Bioprocess technology implementation is hard. Get ahead by getting it right.

How do you know if you’re making the right decisions about bioproduction technologies? There is no universal path to success. As a decision maker you are tasked with figuring out how to move forward from development to production in the most efficient way possible, while facing regulatory pressure and a need to trust the provider that support you. We get it. Our job is to make your job easier.

Join us at Process Progress ‘21 to gain insight, intel and inspiration. Understand how Thermo Fisher's industry knowledge, global manufacturing network, and best-in-class portfolio can help you anticipate and prepare for production challenges. Advance your projects by applying unique strategies—including adaptive innovation and tailored solutions—to your greatest challenges. When you’re developing vaccines and biotherapeutics, you need a provider who has the experience to improving workflows, finding efficiencies, and increasing quality, while providing regulatory support to bring your life-changing products to market faster. This is what we do, because ultimately, your success is our success. Together, we’ll reach new frontiers—and together, we’ll pave the way forward.

What to Expect


  • Deep dive into today’s challenges and learn best practices from thoughtfully chosen industry leaders including regulatory experts, biotech strategists, and a patient’s perspective. Participate in live Q&A sessions focused on accelerating process development, adoption of innovative technologies, and tackling the challenge of assurance of supply.


  • Investigate the technologies and techniques required to scale up production and accelerate speed to market to meet patient needs.


  • Log on to participate in live sessions, explore solutions, deep dive into technical content, and network with peers. You will log off with a valuable mix of ideas and solutions to help you tackle the challenges of next gen biotherapeutic manufacturing.



Scott Gottlieb, M.D., CMS

Physician, Former Commissioner of the FDA (2017-2019); Former Senior Advisor, CMS; Contributor, CNBC & Face the Nation


Peter Dashwood

MS&T Lead at Cell and Gene Therapy, Catapult


Nikki Nogal, Ph.D.

Senior Consultant, CMC Consulting, Latham BioPharm Group


Eric Langer, MSB

President and Managing Partner, BioPlan Associates, Inc.


Ho-Young 'Grace' Lee, Ph.D.

Cell Therapy Analytical Development Group Leader, Senior Scientist, Genentech


Matthew Moon

UCAR-T Therapy Patient